WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 556341
CAS#: 147695-92-9
Description: ZM-226600 is a potent Kir6 (KATP) channel opener (EC50 = 0.5 μM), devoid of antiandrogen properties. ZM226600 is more active than oxybutynin in reducing bladder overactivity, and it is devoid of vascular side effects observed with pinacidil. Its short duration of action (about 1 h) is probably the main problem to solve, in order to consider this compound a valid alternative to antimuscarinics in the therapy of bladder overactivity.
MedKoo Cat#: 556341
Name: ZM-226600
CAS#: 147695-92-9
Chemical Formula: C16H14F3NO4S
Exact Mass: 373.0596
Molecular Weight: 373.3462
Elemental Analysis: C, 51.47; H, 3.78; F, 15.27; N, 3.75; O, 17.14; S, 8.59
Synonym: ZM-226600; ZM 226600; ZM226600;
IUPAC/Chemical Name: N-(4-Phenylsulfonylphenyl)-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide
InChi Key: LJLXQHHFAKVTNP-UHFFFAOYSA-N
InChi Code: InChI=1S/C16H14F3NO4S/c1-15(22,16(17,18)19)14(21)20-11-7-9-13(10-8-11)25(23,24)12-5-3-2-4-6-12/h2-10,22H,1H3,(H,20,21)
SMILES Code: O=C(NC1=CC=C(S(=O)(C2=CC=CC=C2)=O)C=C1)C(C)(O)C(F)(F)F
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 373.3462 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Dyhring T, Jansen-Olesen I, Christophersen P, Olesen J. Pharmacological Profiling of KATP Channel Modulators: An Outlook for New Treatment Opportunities for Migraine. Pharmaceuticals (Basel). 2023 Feb 1;16(2):225. doi: 10.3390/ph16020225. PMID: 37259373; PMCID: PMC9966414.
2: Badawi JK, Ding A, Bross S. Inhibitory effects of different ATP-sensitive potassium channel openers on electrically generated and carbachol-induced contractions of porcine and human detrusor muscle. Fundam Clin Pharmacol. 2008 Feb;22(1):75-86. doi: 10.1111/j.1472-8206.2007.00558.x. PMID: 18251724.
3: Jansen-Olesen I, Mortensen CH, El-Bariaki N, Ploug KB. Characterization of K(ATP)-channels in rat basilar and middle cerebral arteries: studies of vasomotor responses and mRNA expression. Eur J Pharmacol. 2005 Oct 31;523(1-3):109-18. doi: 10.1016/j.ejphar.2005.08.028. Epub 2005 Oct 13. PMID: 16226739.
4: Pinna C, Sanvito P, Bolego C, Cignarella A, Puglisi L. Effect of the ATP- sensitive potassium channel opener ZM226600 on cystometric parameters in rats with ligature-intact, partial urethral obstruction. Eur J Pharmacol. 2005 May 23;516(1):71-7. doi: 10.1016/j.ejphar.2005.04.011. PMID: 15913601.
